State Street’s Protalix BioTherapeutics PLX Stock Holding History

State Street’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.29M	Buy	983,582 +10,767	+1%	+$22.8K	﹤0.01%	3298
2026 Q1	$2.11M	Buy	972,815 +387,554	+66%	+$962K	﹤0.01%	3283
2025 Q4	$1.05M	Buy	585,261 +86,714	+17%	+$177K	﹤0.01%	3519
2025 Q3	$1.11M	Buy	498,547 +54,308	+12%	+$88.4K	﹤0.01%	3489
2025 Q2	$657K	Buy	+444,239	New	+$909K	﹤0.01%	3567
2024 Q2	–	Sell	-826,581	Closed	-$1.04M	–	4386
2024 Q1	$1.04M	Hold	826,581	–	–	﹤0.01%	3460
2023 Q4	$1.47M	Buy	826,581 +66,607	+9%	+$104K	﹤0.01%	3395
2023 Q3	$1.26M	Buy	759,974 +28,737	+4%	+$51.6K	﹤0.01%	3465
2023 Q2	$1.46M	Buy	+731,237	New	+$1.74M	﹤0.01%	3507

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street's PLX Position: Q2 2026 in Review

State Street increased its Protalix BioTherapeutics (PLX) stake by 1.1% in Q2 2026, buying an estimated $22.8K and bringing the position to 983,582 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #3298.

State Street first reported a position in PLX in Q2 2023 and has held it in 9 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

State Street held 983,582 shares of Protalix BioTherapeutics worth $2.29M as of Q2 2026.
State Street bought 10,767 Protalix BioTherapeutics shares in Q2 2026, an estimated $22.8K.
Protalix BioTherapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3298 holding.
State Street first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 9 quarters since.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.